Value Proposition:· Significant cost savings and time savings compared to standard adoptive T cell therapies· Improved accessibility for patients who cannot reach treatment centers offering adoptive T cell therapies· Direct tumor targeting, limiting systemic clearance and minimizing off-target toxicity.· Increased drug loading ratios...
Value Proposition:
· Platform technology for prophylactic and therapeutic vaccination with large RNA payloads.
· Can deliver several types of nucleic acid payloads including self-amplifying mRNA, plasmid, linear DNA, siRNA, miRNA, mRNA.
· Adaptable as a therapeutic delivery strategy for genetic, musculoskeletal, and neurological disorders.
Unmet...
Value Proposition:
· Elicits production of anti-Fentanyl antibodies
· Leads to long-lasting anti-opioid responses without toxicity
· Exhibits 1000-fold increase in antibody production over conventional drug vaccines
Technology Description
Researchers at Johns Hopkins have developed a polymeric fentanyl vaccine. Upon a primary...
Unmet Need
Melanoma is an aggressive form of skin cancer that is characterized by high multidrug resistance and low survival rates. The median survival time for metastatic melanoma patients is approximately 8-9 months with a 3-year overall survival rate of less than 15%. As such, there is a compelling need for novel targeted melanoma therapies.
...
